This article is more than 5 years old. Information may no longer be current.

AnaptysBio names chief financial officer

AnaptysBio has appointed Robert E. Hoffman as chief financial officer, according to a press release.

AnaptysBio recently announced funding for antibody research of an anti-interleukin (IL)-33 program in adults with severe asthma and peanut allergy and anti-IL-36 receptor program to proof of concept in patients with generalized pustular psoriasis.

“Robert brings tremendous strategic operational insight in biotech finance to AnaptysBio,” Hamza Suria, president and CEO of AnaptysBio, said in the release. “He will play a key leadership role as we advance our wholly-owned therapeutic antibody pipeline to key clinical inflection points, including our first-in class anti-IL-33 and anti-IL-36 receptor antibody programs.”

Hoffman had previously served as chief financial officer of Arena Pharmaceuticals and Polaris Group, according to the release.

Reference: www.anaptysbio.com